What’s the current market cap for Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals (CPRX) has a market cap of $3.8bn as of June 19, 2026.

What is the P/E ratio for Catalyst Pharmaceuticals stock?

The price to earnings (P/E) ratio for Catalyst Pharmaceuticals (CPRX) stock is 18.14 as of June 19, 2026.

Does Catalyst Pharmaceuticals stock pay dividends?

No, Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders as of June 19, 2026.

When is the next Catalyst Pharmaceuticals dividend payment date?

Catalyst Pharmaceuticals (CPRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (CPRX) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Catalyst Pharmaceuticals stock | $CPRX Share Price

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Ticker

$CPRX

Sector

Health

Primary listing

NASDAQ

Employees

182

Headquarters

Coral Gables, United States

Website

catalystpharma.com

CPRX Metrics

BasicAdvanced

$3.8bn

18.14

$1.73

0.72

-

What the Analysts think about CPRX

Analyst ratings (Buy, Hold, Sell) for Catalyst Pharmaceuticals stock.

Bulls say / Bears say

Catalyst resolved patent litigation with Lupin Pharmaceuticals, delaying any generic launch of FIRDAPSE in the U.S. until February 2035, preserving market exclusivity for almost another decade.

The company settled with Hetero Labs on the last outstanding ANDA challenges, securing a clear generic entry date of January 2035 for FIRDAPSE and effectively closing all litigation until then.

Angelini Pharma, an Italian drugmaker, agreed to acquire Catalyst for about $4.1 billion ($31.50 per share), highlighting the strategic value of Catalyst's rare disease portfolio and providing a significant premium to shareholders.

FYCOMPA is facing major revenue pressure from generic competitors, with 2026 guidance lowered to $40 million–$45 million as tablet generics take market share.

Angelini Pharma's all-cash acquisition at $31.50 per share represents a 21% premium over the unaffected share price, but it limits near-term upside and is subject to standard closing conditions such as regulatory and shareholder approvals, adding execution risk.

FIRDAPSE adoption is still limited, reaching about 30% in idiopathic LEMS and under 10% in cancer-associated LEMS, showing persistent patient identification challenges that restrict growth potential.

Data summarised monthly by Lightyear AI. Last updated on 30 May 2026.

CPRX Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

CPRX Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

CPRX News

AllArticlesVideos

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

Business Wire·1 month ago

CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Business Wire·1 month ago

Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion Deal

WSJ·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Catalyst Pharmaceuticals

Ticker

Employees

CPRX Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about CPRX

Analyst Ratings

Bulls say / Bears say

CPRX Financial Performance

Income Statement

CPRX Earnings Performance

Earnings per share (EPS)

CPRX News

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion Deal

Buy $CPRX

Lightyear

Legal

Work with us

Bulls say / Bears say

Catalyst Pharmaceuticals/$CPRX

About Catalyst Pharmaceuticals

Ticker

Employees

CPRX Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about CPRX

Analyst Ratings

Bulls say / Bears say

CPRX Financial Performance

Income Statement

CPRX Earnings Performance

Earnings per share (EPS)

CPRX News

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

CPRX Stock Alert: Halper Sadeh LLC is Investigating Whether Catalyst Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion Deal

What’s the current market cap for Catalyst Pharmaceuticals stock?

What is the P/E ratio for Catalyst Pharmaceuticals stock?

Does Catalyst Pharmaceuticals stock pay dividends?

When is the next Catalyst Pharmaceuticals dividend payment date?

What is the beta indicator for Catalyst Pharmaceuticals?

Bulls say / Bears say